Technicals
Oscillators
Bearish
Bearish
5
Neutral
5
Bullish
4
Overall
Bearish
Bearish
31
Neutral
5
Bullish
10
Moving Averages
Bearish
Bearish
26
Neutral
0
Bullish
6
Forecasts
Financial Statements
AI Powered Summary
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Ask AI
Consolidated Quarterly Results (in ₹ Crores)
View Standalone
View Standalone
Consolidated Profit Loss (in ₹ Crores)
View Standalone
View Standalone
Consolidated Balance Sheet (in ₹ Crores)
View Standalone
View Standalone
Consolidated Cash Flows (in ₹ Crores)
View Standalone
View Standalone
Projection
Documents
Investor Presentation
Q1 FY17
Investor Presentation
Q4 FY16
Investor Presentation
Q3 FY16
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI


Frequently Asked Questions about Mangalam Drugs and Organics Ltd
Mangalam Drugs and Organics Ltd (MANGALAM) is currently trading at 29.37 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mangalam Drugs and Organics Ltd is a chemical manufacturing company specializing in active pharmaceutical ingredients, perfumery, dye intermediates, and bulk drug intermediates. Established in 1972, its key facilities are located in Vapi and Sangamner. The company has a strong manufacturing setup with significant production capacity expansions over the years, signaling its strategic focus on growth and scale in bulk drugs. Mangalam has demonstrated a commitment to innovation by establishing an Intellectual Property Rights cell and securing WHO approvals for several active pharmaceutical ingredients since 2017. The firm's extensive product portfolio includes chloroquine phosphate, aluminum chloride anhydrous, and other API intermediaries, positioning it as a versatile player in the pharma industry.
Over the past 52 weeks, Mangalam Drugs and Organics Ltd has traded between a low of ₹22.70 and a high of ₹94.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mangalam Drugs and Organics Ltd has a market capitalization of approximately 46.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mangalam Drugs and Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.50 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 46.49 Cr, Mangalam Drugs and Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mangalam Drugs and Organics Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mangalam Drugs and Organics Ltd is -1.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

